Data on the role of hypothyroidism in the pathogenesis of non-alcoholic fattyliver disease (NAFLD) and liver fibrosis are conflicting, although selectiveThyroid Hormone Receptor (THR)-β agonists have been identified as potentialtherapy in patients with non-alcoholic steatohepatitis (NASH). This evidence concerns the gene NR4A1 and metabolic dysfunction-associated steatohepatitis.